LongBio Pharma (Suzhou) Co., Ltd.

HK$56.95As of Sun 8 Nov 2026, 12:00 UTC
HKEX:1779Healthcare
Country Hong Kong
PE (Fwd) •••
TSR 10Y CAGR —
Div yield —
ROE —
Biotechnology
Beta (5Y) —
PE TTM —
TSR TTM —
Mkt cap HK$4.347B
ROIC —
SE Grade™
Value
Quality
Moat
Consensus
Reference
$62
9.69%
(93.95%)
Hold 3|0|5|4|9
4Q25
1Q26
2Q26
3Q26
Earnings per share¥
0.87
0.85
0.85
0.93
18.44%
10.37%
10.54%
12.05%
Revenue¥M
252.5
249.4
257.7
261.9
6.05%
5.81%
8.93%
4.92%
Peers (US$554.4M)
Cap (US$)
PE
Capital
TTM
5Y
10Y
Leveragex
0.395
0.011
0.011
EBIT/Intx
11.81
0.561
0.607
Own earn%
(90.05)
21.87
25.41
Sh yield%
7.28
23.93
23.70
Owners
Insiders/Inst%
2.63
60.90
Short interest%
3.66
SBC / revenue%
5.37
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
6
Op margin range%
2–7
$1 testx
0.0
Incr. ROIC%
13